Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Antiviral Res ; 177: 104755, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32112797

RESUMEN

Genital herpes is one of the most common sexually transmitted infections (STIs), and it is mainly caused by the neurotropic herpes simplex virus (HSV-2). Not only does this infection cause ulcers, but HSV-2 can also stay in a latent state in the nervous system of the host throughout their lifespan. As a result, many people do not know that they harbor this infection. Moreover, HSV-2 serves as a major risk factor for human immunodeficiency virus (HIV) infection and can be transmitted to the fetus. Despite the high risk of infection and adverse effects, attempts at development of an effective vaccine for HSV-2 have not yet been successful. In this study, we developed a DNA vaccine for HSV-2 (SL-V20). This multivalent DNA vaccine effectively reduced the pathological symptoms of infection and induced efficient elimination of the virus in a mouse model. Intramuscular injection of SL-V20 led to induction of an HSV-2-specific T-cell response in the vagina, the major infection site, and in draining lymph organs. Dendritic cells (DCs), especially basic leucine zipper ATF-like transcription factor 3 (Baft3)+ DCs and partially interferon regulatory factor 4 (Irf4)+ DCs, were involved in this T-cell-mediated protective response, while B cells were dispensable for these prophylactic effects. This study demonstrates that SL-V20 offers a novel and effective vaccine against vaginal HSV-2 infection and may be applicable to patients, pending validation in clinical studies.


Asunto(s)
Anticuerpos Antivirales/sangre , Herpes Genital/prevención & control , Linfocitos T/inmunología , Vagina/inmunología , Vacunas Virales/inmunología , Animales , Femenino , Herpes Genital/inmunología , Herpesvirus Humano 2 , Ratones , Ratones Endogámicos C57BL , Vacunas Combinadas/administración & dosificación , Vacunas Combinadas/inmunología , Vacunas de ADN/administración & dosificación , Vacunas de ADN/inmunología , Vacunas Virales/administración & dosificación
2.
Viruses ; 11(9)2019 09 10.
Artículo en Inglés | MEDLINE | ID: mdl-31509992

RESUMEN

Influenza is an infectious respiratory illness caused by the influenza virus. Though vaccines against influenza exist, they have limited efficacy. To additionally develop effective treatments, there is a need to study the mechanisms of host defenses from influenza viral infections. To date, the mechanism by which interleukin (IL)-33 modulates the antiviral immune response post-influenza infection is unclear. In this study, we demonstrate that exogenous IL-33 enhanced antiviral protection against influenza virus infection. Exogenous IL-33 induced the recruitment of dendritic cells, increased the secretion of pro-inflammatory cytokine IL-12, and promoted cytotoxic T-cell responses in the local microenvironment. Thus, our findings suggest a role of exogenous IL-33 in the antiviral immune response against influenza infection.


Asunto(s)
Anticuerpos Antivirales/sangre , Inmunidad Mucosa/efectos de los fármacos , Interleucina-33/farmacología , Infecciones por Orthomyxoviridae/inmunología , Infecciones por Orthomyxoviridae/prevención & control , Linfocitos T Citotóxicos/inmunología , Animales , Anticuerpos Antivirales/inmunología , Líquido del Lavado Bronquioalveolar/virología , Citocinas/inmunología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Virus de la Influenza A , Masculino , Ratones , Ratones Endogámicos C57BL , Organismos Libres de Patógenos Específicos , Linfocitos T Citotóxicos/efectos de los fármacos , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA